Mechanisms Of Cannabinoid Cb 2 Receptor-Mediated Reduction Of Dopamine Neuronal Excitability In Mouse Ventral Tegmental Area

Zegang Ma
Fenfei Gao
Brett Larsen
Ming Gao
Zhihua Luo

See next page for additional authors

Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology

Recommended Citation
Ma, Zegang; Gao, Fenfei; Larsen, Brett; Gao, Ming; Luo, Zhihua; Chen, Dejie; Ma, Xiaokuang; Qiu, Shenfeng; Zhou, Yu; Xie, Junxia; Xi, Zheng Xiong; and Wu, Jie, "Mechanisms Of Cannabinoid Cb 2 Receptor-Mediated Reduction Of Dopamine Neuronal Excitability In Mouse Ventral Tegmental Area" (2019). Neurobiology. 448.
https://scholar.barrowneuro.org/neurobiology/448

This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact molly.harrington@dignityhealth.org, andrew.wachtel@dignityhealth.org.
Authors
Zegang Ma, Fenfei Gao, Brett Larsen, Ming Gao, Zhihua Luo, Dejie Chen, Xiaokuang Ma, Shenfeng Qiu, Yu Zhou, Junxia Xie, Zheng Xiong Xi, and Jie Wu
Mechanisms of cannabinoid CB_2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area

Zegang Ma a,b, Fenfei Gao c,b, Brett Larsen b,d, Ming Gao b, Zhihua Luo c, Dejie Chen b,e, Xiaokuang Ma a,b,c,d, Shenhong Qiu d, Yu Zhou a, Junxie Xie a, Zheng-Xiong Xi f, Jie Wu a,b,c,e,*

a Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, Shandong Provincial Collaborative Innovation Center for Neurodegenerative Diseases and State Key Disciplines: Physiology, Medical College of Qingdao University, Qingdao 266071, China
b Department of Neurology, St. Joseph’s Hospital and Medical Center, Barrow Neurological Institute, Phoenix, AZ 85013, USA
c Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong 210854, China
d Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ 85004, USA
e Department of Neurology, Yunfu People’s Hospital, Yunfu, Guangdong 527300, China
f Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD 21224, USA

A R T I C L E   I N F O

Article history:
Received 10 January 2019
Received in revised form 24 February 2019
Accepted 14 March 2019
Available online 3 April 2019

Keywords:
Cannabinoid
CB_2 receptor
Ventral tegmental area
Dopamine neuron

A B S T R A C T

Background: We have recently reported that activation of cannabinoid type 2 receptors (CB_2Rs) reduces dopamine (DA) neuron excitability in mouse ventral tegmental area (VTA). Here, we elucidate the underlying mechanisms.

Methods: Patch-clamp recordings were performed in mouse VTA slices and dissociated single VTA DA neurons.

Findings: Using cell-attached recording in VTA slices, bath-application of CB_2R agonists (JWH133 or five other CB_2R agonists) significantly reduced VTA DA neuron action potential (AP) firing rate. Under the patch-clamp whole-cell recording model, JWH133 (10 μM) mildly reduced the frequency of miniature excitatory postsynaptic currents (mEPSCs) but not miniature inhibitory postsynaptic currents (mIPSCs). JWH133 also did not alter evoked EPSCs or IPSCs. In freshly dissociated VTA DA neurons, JWH133 reduced AP firing rate, delayed AP initiation and enhanced AP after-hyperpolarization. In voltage-clamp recordings, JWH133 (1 μM) enhanced M-type K_+ currents (mEPSCs) but not miniature inhibitory postsynaptic currents (mIPSCs). JWH133 also did not alter evoked EPSCs or IPSCs. In freshly dissociated VTA DA neurons, JWH133 reduced AP firing rate, delayed AP initiation and enhanced AP after-hyperpolarization. In voltage-clamp recordings, JWH133 (1 μM) enhanced M-type K_+ currents and this effect was absent in CB_2R−/− mice and abolished by co-administration of a selective CB_2R antagonist (10 μM, AM630). CB_2R-mediated inhibition in VTA DA neuron firing was mimicked by M-current opener (10 μM retigabine) and blocked by M-current blocker (30 μM XE991). In addition, enhancement of neuronal cAMP by forskolin (10 μM) reduced M-current and increased DA neuron firing rate. Finally, pharmacological block of synaptic transmission by NBQX (10 μM), D-APV (50 μM) and picrotoxin (100 μM) in VTA slices failed to prevent CB_2R-mediated inhibition, while intracellular infusion of guanosine 5’-O-2-thiodiphosphate (600 μM, GDP-β-S) through recording electrode to block postsynaptic G-protein function prevented JWH133-induced reduction in AP firing.

Interpretation: Our results suggest that CB_2Rs modulate VTA DA neuron excitability mainly through an intrinsic mechanism, including a CB_2R-mediated reduction of intracellular cAMP, and in turn enhancement of M-type K_+ currents.

Fund: This research was supported by the Barrow Neuroscience Foundation, the BNI-BMS Seed Fund, and CNSF (81771437). © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The CB_2R is a G-protein-coupled receptor that was cloned in 1993 [5]. Since then, the expression and function of CB_2Rs in the brain has been debated. Early studies suggested that CB_2Rs were absent in the brain because CB_2 mRNA transcripts were not detected in brain tissues [1–4]. Based on these findings, the CB_2R has been considered as a “peripheral” cannabinoid receptor [5–7]. Recently, this concept has been challenged by the identification of CB_2R mRNA and receptor proteins throughout the central nervous system (CNS) [8,9], including the cerebral cortex [10], hippocampus [11], striatum [12], amygdala and brainstem [12–17]. Immunoblot and immunohistochemistry (IHC) assay also detect CB_2R-immunoreactivity or immunostaining in various
Research in context

Evidence before this study

Cannabis sativa (marijuana) is a fibrous flowering plant that naturally produces an abundant variety of molecules, some with psychoactive effects. At least 4% of the world’s adult population uses cannabis annually, making it one of the most frequently used illicit drugs in the world. The psychoactive effects of cannabis are mediated primarily through two cannabinoid receptor (CBR) subtypes, CB1R and CB2R. The prevailing view is that CB1Rs are mainly expressed in central neurons while CB2Rs are predominantly expressed in peripheral immune cells. However, this traditional view has been challenged by strong emerging evidence that shows CB2Rs are moderately expressed and function in specific brain areas. New evidence has demonstrated that brain CB2R mediate important modulations in animal cocaine-seeking behaviors (Xi et al., Nature of Neuroscience, Jul 24;14[9]:1160-6, 2011), suggesting that these receptors may exist in the brain regions that regulate drug addiction. Recently, we further confirmed that functional CB2Rs are expressed in mouse ventral tegmental area (VTA) DA neurons, and activation of VTA CB2Rs reduces neuronal excitability and cocaine-seeking behavior (Zhang et al., PNAS 111[46]:E5007-15, 2014). However, the mechanisms and the CB2R-G protein intracellular signaling that underlies these VTA CB2R-mediated modulations are unknown.

Added value of this study

In this study, we elucidate the underlying mechanisms. Using cell-attached recording in VTA slices, bath-application of a CB2R agonist (JWH133) inhibited VTA DA neuron firing in a concentration-dependent manner. In addition to JWH133, five other CB2R agonists exhibited similar inhibition. Under the patch-clamp whole-cell recording mode, JWH133 (10 μM) inhibited miniature excitatory postsynaptic currents (mEPSCs) but not miniature inhibitory postsynaptic currents (mIPSCs). However, JWH133 did not inhibit evoked EPSCs or IPSCs. In freshly dissociated VTA DA neurons, JWH133 reduced the action potential (AP) firing rate, delayed AP initiation and enhanced AP after-hyperpolarization. In voltage-clamp recordings, M-type K+ currents were enhanced by JWH133. This effect was absent in CB2−/− mice and abolished by co-administration of a selective CB2R antagonist (AM630). In addition, CB2R-mediated inhibition in VTA DA neuron firing can be mimicked by an M-current opener and blocked by an M-current blocker. Finally, CB2R-cAMP signaling plays a role in modulating DA neuron excitability since enhancement of cAMP by forskolin reduced M-current and increased DA neuron firing rate.

Implications of all the available evidence

These results suggest that CB2Rs modulate VTA DA neuron excitability through both synaptic and intrinsic mechanisms, including a reduction in presynaptic glutamate release and enhancement of postsynaptic neuronal M-currents. This work provides new insights into understanding the impact of brain CB2Rs in a variety of DA system associated disease pathogenesis and potential therapeutics.

level of cocaine self-administration and cocaine-enhanced locomotion compared to wild type (WT) mice [22]. Recently, we identified functional CB2R expression in mouse VTA DA neurons, and selective activation of these CB2Rs reduced DA neuronal excitability in vitro and in vivo preparations [25]. More recently, Stempel et al. reported that CB2Rs mediated a cell type-specific plasticity in the hippocampal CA3 neurons [11]. However, the cellular and molecular mechanisms underlying CB2R modulation of VTA DA neuronal excitability are poorly understood.

In the present study, we systematically investigated synaptic and intrinsic ionic channel mechanisms possibly underlying CB2R modulation of VTA DA neurons using patch-clamp recordings. We found that activation of VTA CB2Rs reduced the frequency of mEPSCs but not mIPSCs in DA neurons. By using a perforated patch-clamp recording in acutely dissociated VTA DA neurons, a simple single cell model without intact presynaptic connections, we found that JWH133 reduced DA neuron action potential (AP) firing rate, prolonged AP initiation, enhanced after-hyperpolarization, and enhanced M-type K+ channel currents. In addition, we determined whether the presynaptic (reduction of mEPSC frequency) or postsynaptic (intrinsic) or both contribute to JWH133-induced reduction in AP firing, and found that the intrinsic mechanism such as enhancement of M-current, contributes to CB2R-mediated reduction of VTA DA neuronal excitability, which may play an important role in the regulation of DA-associated behaviors and diseases.

2. Methods and materials

2.1. Animals

Male wild-type (WT) and Zimmer strain CB2−/− mice [6,7] with C57BL/6J genetic backgrounds were bred at Barrow Neurological Institute. Genotyping was performed in our laboratory before experiments were begun. All experiments were in compliance with the Guide for the Care and Use of Laboratory Animals and experimental protocol has been approved by IACUC of Barrow Neurological Institute. When we tested the effects of CB2 agonist on VTA DA neurons using CB2−/− mice, the littermate WT mice were used as the control. All experimental procedures were approved by the Institutional Animal Care and Use Committee at the Barrow Neurological Institute and by the Animal Ethics Committee of Qingdao University.

2.2. VTA slice preparation

Mice (14-31 days old) were used as previously described [26-28]. Briefly, mice were housed under standard conditions at 22–24 °C and 50–60% humidity under a 12 h light/dark cycle. On the experimental day, mice were anesthetized (isoflurane USP) and then sacrificed by decapitation. Horizontal (or coronal) midbrain slices (250 μm) were cut using a vibratome 1000 (Vibratome 1000 plus; Ted Pella Inc., Redding, CA) to include the VTA. Slices were prepared in an ice-cold, sucrose-based, artificial cerebrospinal fluid containing (in mM): 212.7 sucrose, 5 KCl, 1.25 NaH2PO4, 3 MgCl2, 1 CaCl2, 26 NaHCO3, and 10 glucose. The slices were then incubated for at least 1 h in a pre-incubation chamber (Warner Ins., Holliston, MA) at room temperature (22–24 °C) in conventional artificial cerebrospinal fluid containing (ACSF, in mM): 124 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3 and 10 glucose. The ACSF was continuously saturated with 95% O2 and 5% CO2.

2.3. Cell-attached patch-clamp recordings in VTA slices

For slice patch recordings, horizontal or coronal midbrain slices (250 μm thickness) were prepared from 14- to 31-day old mice (WT and CB2−/−) mice as described previously [28]. To maintain an intact intracellular environment, we employed a cell-attached mode of patch recording. Thus, we were able to measure stable extracellular action
potential (AP) firing for hours. The recording pipette was filled with intracellular solution containing in mM: 140 potassium gluconate, 5 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 MgATP, 0.3 Na2GTP and 10 Na2-phosphocreatine (pH 7.3 with KOH). After patch recording, we converted from cell-attached mode to conventional whole-cell recording to identify the neuronal phenotype of the recorded neuron according to standard electrophysiological, pharmacological and immunostaining criteria as described previously [28,29]. Briefly, in this study, we mostly recorded DA neurons from lateral VTA, which demonstrated a low action potential (AP) firing rate (1−3 Hz), large H-current, and TH positive reaction by immunostaining (Fig. 1A-C). We have analyzed 12 VTA neurons (from 12 mice), under the cell-attached recording mode to record extracellular AP firing, the averaged AP duration was 2.34 ± 0.07 ms, the averaged firing rate was 1.65 ± 0.14 Hz, and after perfusion of 100 nM quinpirole for 10 min, the AP firing rate was reduced to 0.53 ± 0.08 Hz (paired t-test p < 0.0001). After washout of quinpirole for 10 min, AP firing rate recovered to 1.40 ± 0.12 Hz (quinpirole washout p < 0.0001). In addition, we have examined the effects of JWH133 on H-currents of DA neurons in mouse VTA slices. In 4 cells tested (from 2 mice), the amplitudes of H-currents (hyperpolarizing from −60 to −120 mV) before and after exposure of 10 μM JWH133 for 10 min were 166.0 ± 24.3 pA and 161.3 ± 11.2 pA (paired t-test, p = 0.86). These results suggest that acute application of 10 μM JWH133 to VTA slices did not alter H-current.

2.5. Patch-clamp recording from single dissociated VTA DA neurons

Perforated-patch whole-cell recording techniques were employed [30,31]. Compared to performing conventional whole-cell recordings, this approach was crucial to obtain stable nicotinic responses from dissociated VTA neurons, presumably due to minimal perturbation of the intracellular environment. Pipettes (3−5 MΩ) used for perforated-patch recordings were filled with intracellular recording solution, which contained (in mM): 140 K-gluconate, 10 KCl, 5 MgCl2, and 10 HEPES; pH 7.2 (with Tris-OH) freshly supplemented before use with amphotericin B to 200 μg/ml from a 40 mg/ml DMSO stock. The liquid junction potential was 14 mV and calculated using Clamplex 9.2 (Axon Instruments, Foster City, CA), and corrections were made for junction potentials post-hoc. After tight seal (>2 GΩ) formation, about 5−20 min was required for conversion to the perforated-patch mode, and an access resistance of <60 MΩ was accepted to start the experiments. Series resistance was not compensated in this study. Data were acquired at 10 kHz, filtered at 2 kHz, digitized on-line (Digidata 1440 series A/D board, Axon Instruments), and displayed and stored on a PC computer. Rapid application of drugs was performed using a computer-controlled “U-tube” system [30]. Periods of drug exposure are specified in the text and figures or legends. All experiments were performed at room temperature (21 ± 1 °C). To enable identification of single, dissociated VTA neurons, cells were labeled with biocytin (Sigma-Aldrich, St. Louis, MO; 2.0 mg/ml in the recording electrode) in some experiments. After conversion from perforated to a conventional whole-cell recording mode, the dye was injected into the cytoplasm by a pulse (200 ms, 0.5 Hz) of depolarizing current (1.0 nA) for 3 min. Labeled cells were visualized using epifluorescence microscopy (see detail in our recent publication) [25].

2.6. Data analyses and statistics

All data are presented as means (± S.E.M.). One-way or two-way analysis of variance (ANOVA) was used to analyze the significance of the effects of JWH133 or other drugs on neuronal firing. Individual group comparisons were carried out using the Student Newman-Keuls or Tukey method. In addition, paired (or unpaired) t-tests were also

---

**Fig. 1.** Identification of VTA DA neurons from patch-clamp recording in VTA slice. (a) In patch-clamp cell-attached recording mode, bath-application of 100 nM quinpirole (dopamine D2 receptor agonist) inhibited firing rate of DAergic neurons. (b) Under whole-cell recording mode, DA neurons exhibited hyperpolarizing pulse-activated currents (H-current, left traces) whereas GABAergic neurons usually did not express H-currents (Right traces). (c) After patch recording, the biocytin (2 mg/ml) was delivered into recorded neuron (left panel). Tyrosine hydroxylase (TH) staining was performed post hoc and labels DA neurons (middle and right panels).
used to analyze some electrophysiological data as described previously [30,31].

3. Results

3.1. Activation of CB2R reduced VTA DA neuron firing

Initial experiments were designed to examine the concentration-dependent effect of CB2R agonist (JWH133) on VTA DA neuron firing using cell-attached recording mode. Fig. 2A shows a typical trace of VTA DA firing before (A top trace) and during (A bottom trace) CB2R agonist JWH133 exposure. Bath applications of different concentrations of JWH133 (1, 10, 100 μM)-induced inhibition of VTA DA neuron firing rate in a concentration-dependent manner. (b) Comparison of the effects of JWH133 on AP firing rate between horizontal and coronal VTA slices, and showed no significant difference between these two types of slices (e). (f) In addition to JWH133, other 6 CB2R agonists tested showed 4 of them exhibited inhibitory effects on VTA DA neurons. * p < 0.05, ** p < 0.01. (g) In control experiments (without any drugs), cell-attached patch recording showed a stable AP firing of VTA DA neurons for 20 min. (h) Mice were classified into two age groups (postnatal 16 and 30). (i) Statistical comparison of JWH133 (10 μM)-induced inhibition of VTA DA neuron firing rate between these two age-groups, and showed no statistical significance (N.S.).
electrophysiological characteristic features and the TH staining after patch-clamp recording as described previously [25,28] and shown in Fig. 1A-C. In 18 VTA slices tested prepared from 9 WT mice, bath perfusion of 10 μM JWH133 for 10 min altered mEPSCs (Fig. 3A,B), represented as reduced frequency in 14 slices (Fig. 3C,E, left panel) and enhanced frequency in 4 slices. Averaged data showed that JWH133 reduced mEPSC frequency from 0.91 ± 0.19 to 0.75 ± 0.14 Hz (p = 0.03, paired t-test, n = 18, Fig. 3F, left panel). Further cumulative distribution of mEPSC inter-event interval showed significantly shift (K-S test, p = 0.002). For mEPSC amplitude, JWH133 reduced amplitude in 3 slices and enhanced amplitude in 14 slices; and no change in 1 slice (Fig. 3D, E, right panel). These results suggest that acute activation of CB2Rs shows a modest, but statistically significant, reduction in glutamatergic synaptic transmission in VTA DA neurons, including reduced presynaptic glutamate release probability.

3.3. Effects of CB2R activation on inhibitory synaptic transmission in VTA DA neurons

We then examined the effects of JWH133 on miniature inhibitory postsynaptic currents (mIPSCs) in the presence of TTX (1 μM) and picrotoxin (100 μM) before (top trace) and after (bottom trace) JWH133 (10 μM) exposure using the whole-cell patch-clamp recording in a VTA slice. In 23 VTA slices tested prepared from 11 WT mice, bath perfusion of 10 μM JWH133 for 10 min altered mIPSC frequency and amplitude, represented as reduced frequency in 9 slices and enhanced frequency in 14 slices; reduced amplitude in 8 slices and enhancement amplitude in 14 slices; and no change in one slice. After averaged, these data showed that after JWH133 exposure, mIPSC frequency was 109% (109 ± 5%, p = 0.09, paired t-test, n = 23) and amplitude was 101% (101 ± 2%, p = 0.73, paired t-test, n = 23) compared to the baseline level (Fig. 4A, E). Neither inter-event interval nor amplitude cumulative distribution showed shift (Fig. 4B, C). These results suggest that activation of CB2Rs exhibits little effects on either presynaptic GABA release or postsynaptic GABAA receptor function.

3.4. Effects of CB2R activation on evoked EPSCs and IPSCs in VTA DA neurons

We also examined the effects of JWH133 on evoked EPSCs (eEPSCs) and IPSCs (eIPSCs). In these experiments, 100 μM PTX (for eEPSCs) or NBQX (10 μM) + APV (50 μM) (for eIPSCs) was added into the bath solution. A bipolar tungsten stimulation electrode was placed at ~150 μm rostral to the recording electrode and the paired stimulation pulses with 50 ms interval were applied (Fig. 5A). The results showed that bath perfusion of 10 μM JWH133 for 10 min failed to alter the current amplitude and the P2/P1 ratio of paired-pulse-induced eEPSCs (Fig. 5A-C) and eIPSCs (Fig. 5D-F). These results suggest that acute activation of VTA CB2Rs does not affect evoked synaptic neurotransmitter release.
Therefore, we explored the possibility that CB2Rs may also modulate M-currents in VTA DA neurons. M-currents were induced with a standard deactivation voltage protocol [32,36] as shown in Fig. 7A. M-current is measured as the inward relaxation current caused by M-current deactivation during the voltage steps. Bath-applied JWH133 (1 μM) significantly enhanced M-currents elicited by three hyperpolarizing holding potentials in dissociated VTA DA neurons in WT mice (Fig. 7B), and this effect was reversible after JWH133 washout (Fig. 7C). Fig. 7D shows the superimposed traces of M-currents before and during JWH133 exposure, showing a JWH133-induced M-current augmentation. This effect was blocked by AM630 (1 μM) and absent in VTA DA neurons prepared from CB2^−/− mice. To confirm the identity of the recorded M-current, we examined the effects of retigabine (a selective M-current enhancer, 10 μM) and XE991 (a selective M-current blocker, 30 μM) on the recorded current. Like JWH133, retigabine enhanced (n = 5 from 3 mice, p = 0.02, paired t-test), but XE991 reduced (n = 8 from 4 mice, p = 0.003, paired t-test) the recorded currents produced by the M-current-inducing protocol, supporting the conclusion that the recorded currents were, indeed, M-currents. Fig. 7E shows pooled data, illustrating the effects of each individual group tested, in which JWH133 (1 μM) enhanced M-currents (n = 19 from 8 mice, p = 0.0002, paired t-test), AM630 + JWH133 abolished JWH133’s effect, retigabine enhanced but XE991 reduced M-currents in WT mice. While in CB2^−/− mice, JWH133 failed to enhance M-current but retigabine still enhances and XE991 still reduced M-currents. These results suggest that the inhibitory effect of JWH133 on M-current is mediated through the CB2Rs, while the effects of retigabine and XE991 on M-current are CB2R-independent.

3.7. Roles of CB2R-mediated enhancement of M-current in altered VTA DA neuron action potentials

To further determine whether JWH133-enhanced M-currents contribute to JWH133-induced VTA DA neuronal inhibition, we examined the effects of retigabine and XE991 on VTA DA neuronal firing. In single dissociated VTA DA neurons, we found that retigabine (10 μM) increased M-currents, in an amplitude similar to JWH133, causing a reduction in VTA DA neuronal firing, while XE991 (30 μM) attenuated M-currents, producing an increase in neuronal firing (Fig. 8A, B). Fig. 8C and D show the summarized results after statistical analyses that retigabine reduced AP firing rate and prolonged AP initial time, and XE991 increased AP firing rate and shortened AP initial time. These results suggest that M-current in VTA DA neurons play an important role in modulation of neuronal firing rate. In VTA slices, cell-attached recordings showed that, in the presence of XE991, JWH133 failed to inhibit DA neuron firing (Fig. 8E, F). These results suggest that JWH133-enhanced M-currents play a role in the JWH133-induced reduction in VTA DA neuronal firing.

3.8. Intracellular signal pathway of JWH133-induced enhancement of M-current

In these experiments, we determined which second messenger molecule mediates the CB2R-G-protein signaling to M-type K^+ channels. It is known that CB2R activation primarily initiates two signal pathways, MAPK/ERK and cAMP/PKA, producing an increase in the former and decrease in the latter [37–39]. Since cAMP, but not MAPK, is associated to M-type K^+ channels [37,40], we examined the effect of enhanced intracellular cAMP by forskolin on JWH133-induced enhancement of M-current. As shown in Fig. 9, bath-perfusion of 10 μM forskolin to dissociated single VTA DA neuron reduced M-current by 19.2 ± 4.9% and in the presence of forskolin, JWH133 (1 μM) potentiated M-current by 8.1 ± 3.7% (n = 10 from 5 mice, One-Way ANOVA, F[3,27] = 14.9, p < 0.0001). Further analysis showed that forskolin-induced reduction of M-current was significant (p < 0.01, One-way ANOVA, Tukey), while in the presence of forskolin, JWH133-induced change of AP firing was
Fig. 6. Analysis of CB2R-mediated changes of action potential (AP) in dissociated VTA DA neurons. Representative typical traces of AP of VTA DA neurons before (a), during (b) and after (c) exposure of 1 μM JWH133 under perforated current-clamp recording conditions. AP firing was elicited by injection of 10 pA current through recording electrode. Superimposed the first AP from trace (a)-(c) to show the AP initiation (d) and AP after-hyperpolarization (e) with expended time scale. (f) Normalized data showing the effect of JWH133 on AP firing parameters. *p < 0.05, **p < 0.01.

Fig. 7. Effects of JWH133 on M-type K⁺ currents in single dissociated VTA DA neurons. (a)-(c) Representative typical traces of M-currents before, during and after exposure of JWH133. M-currents were induced by a pre-depolarization from holding potential of −60 mV to −30 mV, then three steps back to −60 mV in 10 mV increments. Fig. 7b illustrates that JWH133 increased M-current amplitude in VTA DA neurons. (d) Superimposed M-current before (Black trace) and during (red trace) JWH133 exposure with expanded time scale. (e) Bar graph illustrating that JWH133 (1 μM) enhanced M-currents, which was blocked by AM630 or absent in CB2−/− mice. Retigabine enhanced, while XE991 attenuated M-currents in both WT and CB2−/− mice. The above experiments were performed separately by each paired (before and after tested drug exposure) group. In statistical analyses, the baseline (before drug exposure) was normalized as 1, and the changed value after drug perfusion was compared to the baseline of each individual group, and analyzed using paired t-test.
not significant \((p > 0.05, \text{Fig. 9A,B, One-way ANOVA, Tukey})\). These results suggest that CB2R-mediated reduction of intracellular cAMP likely contributes to the enhancement of M-current by JWH133. Finally, we determined whether forskolin can prevent the JWH133-induced DA firing reduction. As shown in \(\text{Fig. 9C and D, using cell-attached recording in VTA slices, bath-application of forskolin (10 μM) increased DA firing rate and prevented JWH133 (10 μM)-mediated reduction of DA firing rate (n = 11 from 5 mice, One-way ANOVA, F}_{1,20}^{} = 4.63, p = 0.018, \text{Fig. 9C, D}). Further analysis showed that forskolin increased AP firing rate by 8.2 ± 2.0% \((p < 0.05, \text{paired t-test})\), while in the presence of forskolin, JWH133 altered AP firing by 1.2 ± 3.0% \((p > 0.05, \text{paired t-test})\). Together, these results suggest that JWH133 activates CB2R-G-protein signaling, thereby reducing intracellular cAMP levels, in turn enhancing M-type K\(^+\) channel function, and ultimately reducing VTA DA neuronal excitability.

3.9. Do both synaptic and intrinsic mechanisms contribute to CB2R-mediated reduction of VTA DA neuron firing?

To further determine the above findings that presynaptic mechanism (reduced mEPSC frequency) and intrinsic mechanism (enhanced M-current) contribute to CB2R-mediated inhibition in VTA DA neuronal firing, we designed two additional experiments. First, we examined the effects of JWH133 on neuronal firing in the presence of NBQX (10 μM), APV (50 μM) and picrotoxin (100 μM) to block excitatory and inhibitory presynaptic transmissions. We found that under cell-attached recording...
mode, JWH133 (10 μM) still significantly reduced DA neuron AP firing rate (inhibitory rate was 11 ± 2%, n = 21 from 6 mice, p = 0.0001, paired t-test, Fig. 10A), while without this pharmacological cocktail, JWH133-induced reduction in AP firing rate was 18 ± 4% (n = 21 from 8 mice, p = 0.0002, Fig. 10B). Although the block of synaptic transmission did reduce the inhibitory rate by JWH133 from 18 ± 4% (without synaptic block) to 11 ± 2% (with synaptic block), the difference of the inhibitory rate between these two groups (18 ± 4% vs. 11 ± 2%) was not statistical significant (p = 0.165, unpaired t-test). These results suggest that JWH133-induced mild reduction of presynaptic glutamate release seems not to play an important role in the mediation of JWH133-induced reduction in DA neuron firing. Second, we selectively blocked postsynaptic CB2R-G protein function by addition of 600 μM GDP-β-S, an intracellular G-protein blocker, into the recording electrode, thus allowing GDP-β-S to diffuse into the recorded neuron after converted into whole-cell recording mode. As shown in Fig. 10, in the presence of intracellular GDP-β-S, bath application of 10 μM JWH133 failed to alter AP firing rate in VTA DA neurons (from 1.97 ± 0.39 to 2.03 ± 0.44 Hz, p = 0.44, paired t-test, n = 7 from 3 mice, Fig. 10C). However, in the absence of intracellular GDP-β-S, bath application of 10 μM JWH133 reduced VTA DA neural rate (from 1.99 ± 0.23 to 1.70 ± 0.22 Hz, p = 0.004, paired t-test, n = 14 from 4 mice, Fig. 10D). Statistical analysis showed that under whole-cell recording conditions (within 5 min after converted into whole-cell configuration), JWH133 failed to reduce AP firing rate in the presence of intracellular GDP-β-S (Fig. 10E), while JWH133 reduced AP firing in the group neurons that did not contain intracellular GDP-β-S (Fig. 10F). These results suggest that the intrinsic mechanism (CB2R-mediated enhancement of M-current) predominantly underlies the JWH133-induced reduction of VTA DA neuron excitability.

4. Discussion

In this study, we find that acute exposure of the CB2R agonist, JWH133, reduces DA neuronal excitability in the VTA, which is mainly mediated through an intrinsic mechanism. Although JWH133 mildly reduces presynaptic glutamate release probability and results in a decreased glutamatergic synaptic transmission in VTA DA neurons, this may play little role in JWH133-induced reduction of VTA DA neuron firing because pharmacological block of synaptic transmission fails to prevent JWH133-induced inhibitory effect. JWH133 activates a postsynaptic CB2R-R-Ca influx signaling cascade, reduces intracellular cAMP levels, in turn enhances M-type K⁺ channel function, and leading to the reduction of VTA DA neuronal excitability. Through this intrinsic mechanism, CB2Rs significantly reduce VTA DA neuronal excitability, which may underlie CB2R-mediated modulations in mesolimbic DA system function and DA-related behavior and diseases.

VTA DA neuronal firing is controlled by excitatory and inhibitory synaptic innervations. Modulations of these synaptic inputs alter neuronal excitability. Numerous G-protein-coupled receptors such as opioid, 5-HT₂, metabolic glutamate, GABAA and CB1 receptors modulate synaptic transmission by alteration of presynaptic neurotransmitter release. Emerging evidence demonstrates that activation of CB2Rs modulates synaptic transmission in the entorhinal cortex [41], transfected hippocampal Dauld neurons [42] and hippocampal pyramidal neurons from hippocampal slice cultures [43]. Thus, it is reasonable that CB2Rs are expressed in presynaptic terminals/boutons and modulate neurotransmitter release. Indeed, in this study, we found a mild, but statistically significant, reduction in the frequency of mEPSC after exposure to JWH133 (10 μM), suggesting that JWH133-induced reduction in VTA DA neuronal excitability may be mediated, at least in part, through a reduction of glutamatergic synaptic transmission onto DA neurons. However, additional experiments showed that pharmacological block of glutamatergic and GABAergic transmissions by perfusion of NBQX, APV and picrotoxin to VTA slice failed to prevent JWH133 (10 μM)-induced reduction in DA neuron firing rate. These results suggest that JWH133-induced the mild reduction of presynaptic glutamate release does not contribute to the JWH133-induced reduction in DA neuron firing under our experimental conditions. Previous report has shown that the activation of CB2Rs reduced inhibitory synaptic transmission in the entorhinal cortex [41], but this study did not identify the cellular location of the CB2Rs involved [41]. Thus, the pharmacological effects...
reported may be caused by CB2Rs expressed in either cortical neurons or microglia [44] since microglia are capable of modulating synaptic plasticity [45]. Another report demonstrated that selective activation of neuronal CB2Rs reduced inhibitory synaptic transmission via a presynaptic mechanism in transfected hippocampal Daudi neurons prepared from CB1R−/− mice [42]. Compared to these two reports, we found that CB2Rs mildly reduced glutamatergic, but not GABAergic transmission in mouse VTA DA neurons. This discrepancy may be due to several reasons. First, different brain regions or neuronal phenotypes may have varied levels of CB2R expression [46]. This is supported by our recent finding that CB2Rs are highly expressed in the midbrain and moderately expressed in the prefrontal cortex (PFC), while the expression in the striatum is very low [25]. Second, brain CB2R expression is inducible expressed in the prefrontal cortex (PFC), while the expression in the striatum is very low [25]. Second, brain CB2R expression is inducible expressed in the prefrontal cortex (PFC), while the expression in the striatum is very low [25].

suggested that chronic treatment of JWH133 may up-regulate CB2R expression in the hippocampus [43]. Third, different CB2-R agonists, with varying pharmacological actions, were used in separate studies. These pharmacological variances, resulting in the activation of diverse intracellular signal pathways [48], may explain these inconsistent electrophysiological findings. Collectively, our data suggest that glutamatergic presynaptic terminal/boutons may express very low level of CB2Rs, where they mildly modulate glutamate release probability, but contribute little to the alteration of DA neuron firing rate. Interestingly, we did not see a significant effect of JWH133 on mIPSCs, eEPSCs and eIPSCs in VTA DA neurons, which is consistent with previous report that activation of CB2Rs modulated glutamatergic, but not GABAergic synaptic, transmission in hippocampal slices [43]. The reason remains unknown, it may suggest that CB2Rs are mainly distributed on the neuron somato, and only limited CB2Rs are expressed on glutamatergic presynaptic terminals/boutons in VTA DA neurons. Our previous work supports this idea [25] as showed predominant expression of CB2Rs on the VTA DAergic cell body.

In addition to presynaptic effect, VTA DA neuronal excitability is also profoundly modulated by intrinsic postsynaptic mechanisms, including the linkage of G-protein-coupled receptors to ion channels located on the cell membrane. CB2Rs are G-protein-coupled receptors that, when activated, alter G-protein (Gαi/Go)-coupled intracellular signaling cascades [49]. Emerging lines of evidence suggest that in VTA DA neurons, G-protein-coupled receptor signaling modulates neuronal excitability through several types of ion channels, e.g., G-protein-coupled inward rectifying K+ channels (GIRK) [50–52], M-type K+ channels [32,53,54], A-type of K+ channels [55], and L-type voltage-gated Ca2+ channels [56]. In the present study, we found that JWH133 reduced neuron firing in acutely-dissociated VTA DA neurons by prolonging AP initiation, enhancing AHP amplitude and hyperpolarizing membrane potential, suggesting a potentiation of M-type K+ currents. Under voltage-clamp mode, we measured M-current in dissociated VTA DA neurons, and found a CB2-R-dependent enhancement of M-current amplitude by JWH133, confirming that CB2Rs modulate M-current. M-currents are voltage-gated K+ channels that strongly activate on depolarization to repolarize the cell, and potentiate regulate neuronal excitability [57,58]. Since M-type channels are activated at a membrane potential near the threshold for action potential initiation, it has a strong influence on neuronal excitability and responsiveness to synaptic inputs [59,60], and plays a critical role in terminating bursting activity in hippocampal CA1 neurons [61]. Importantly, under resting physiological conditions, M-channels are not fully open. Single channel analysis of both native [53,59] and recombinant [62,63] Kv7.2/Kv7.3 channels demonstrates that the maximal channel open probability is <1.0, suggesting that there is a considerable range to fully activate M-channels, and therefore, regulate neuronal activity. It was reported that VTA DA neurons express M-type K+ channels [32] and these channels play an important role in controlling VTA DA neuronal excitability [64]. It has been reported that activation of G-protein-coupled receptors increases M-currents in hippocampal neurons, by administration of somatostatin [65], corticostatin [66], or dynorphin [67]. This G-protein-mediated enhancement of M-current is important since it reduces neuronal excitability and counteracts convulsions. Indeed, it was also reported that the M-current enhancer, retigabine, shifts the current–voltage curve to the left (so that the channels open at more hyperpolarized membrane potentials) and increases the maximal opening probability [68,69], therefore, producing a strong suppression of neuronal firing [68] and exhibiting a potent anticonvulsant effect [70]. We also compared the effects of JWH133 and retigabine on M-current and VTA DA neuronal firing. We found that JWH133 and retigabine enhanced M-current amplitude and reduced neuronal firing rate. However, in the presence of M-current blocker (XE991), JWH133 failed to inhibit VTA DA neuronal firing. These results suggest that CB2R-mediated enhancement of M-current is an important intrinsic mechanism underlying the CB2R-
mediated reduction in VTA DA neuronal excitability. Then, we further examined the signaling between CB2R activation and M-current enhancement. Based on the previous studies, activation of CB2Rs primarily initiates two signal pathways, MAPK/ERK and cAMP/PKA [37–39,48]. Considering cAMP plays an important role in modulation of M-current [40] and neuronal firing [71,72], we tested whether or not CB2R-induced reduction of cAMP contributes to the enhanced effect of M-current. To reach this goal, we applied forskolin, a CAMP enhancer to the recorded cell to increase intracellular CAMP levels [73]. We tried to address 3 questions: [1] Does forskolin suppress M-current? [2] Does forskolin increase VTA DA neuron firing? [3] Does forskolin prevent JWH133-induced inhibition of VTA DA neuron firing? Our data clearly showed that forskolin (10 μM) reduced M-current and increased VTA DA neuron firing. In the presence of forskolin, JWH133 failed to potentiate M-current and reduce AP firing. These results suggest that CB2R-G-protein-cAMP pathway likely plays a critical role in modulation of M-current and consequently neuronal excitability. Thus, under our experimental conditions (in vitro preparations), the activation of somatodendritic CB2Rs on VTA DA neurons reduces intracellular CAMP levels and enhances M-current amplitude, leading to a reduction in neuronal firing and excitability. However, in vivo conditions may be more complex, for example CB2Rs can modulate neuronal excitability by acting on glial cells [74,75], by modulating endogenous cannabinoid substances or even by acting on peripheral cells.

Our findings that the CB2R-mediated reduction of VTA DA neuronal excitability, the underlying intracellular signaling (cAMP) and target (M-channels) have translational significance. Accumulating lines of evidence demonstrate that CB2Rs mediate a variety of important modulations in DA-associated behaviors [76] including food intake, body weight [77–80], depression [81], anxiety [14,82], and schizophrenia-like behavior [15,83]. Recent reports emerging from several labs, including ours, have shown brain CB2Rs play a pivotal role in the elimination of cocaine, alcohol and nicotine addiction [84–86]. These lines of evidence strongly suggest an important impact of CB2Rs in the mesocorticolimbic system as well as critical roles in various brain functions including psychiatric, cognitive and neurobiological activity. The finding of the CB2R-mediated reduction of midbrain DA neuronal excitability provides an insight into understanding of the roles played by CB2Rs in the above mentioned DA-associated function and diseases. When compared to CB2Rs, brain CB2Rs exhibit highly translational potential to be used in clinical practices since the following unique features: [1] Lower expression levels, suggesting that these receptors may not mediate the effect of cannabis under normal physiological conditions; [2] Highly inducible, meaning that under some pathological conditions (e.g., addiction, inflammation, stroke, schizophrenia, stress, anxiety, etc.), CB2R expression is enhanced in the brain [87], suggesting a close relationship between the alteration of CB2R expression/function and various psychiatric and neurological diseases; and [3] Exhibit special distribution, given that CB2Rs are chiefly expressed in neuronal somatodendritic areas [8] (postsynaptic) but CB2Rs are predominantly expressed on neuronal terminals, especially on GABAergic terminals (presynaptic), which leads to some opposing effects after activation by these two receptor subtypes [88]. Considering these characteristic features, the mesolimbic CB2R appears to be an important substrate for neuroprotection [89], and targeting CB2Rs or manipulations of their signaling (cAMP/PKA) and target (M-channels) will likely offer a novel therapeutic strategy for treating neuropsychiatric and neurological diseases without typical CB1R-mediated side-effects.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.03.040.

Conflicts of interest
All authors have nothing to disclose.

Author contributions
Z.M., F.G., B.L., M.G., Z.L., D.C., X.M., S.Q., Y.Z., Z.X. conducted the experiments, analyzed data, prepared original figures, and revised the manuscript. Z.X. and J.X. participated in the experimental designs, analyzed the data, and revised the manuscript. J.W. designed and conducted the experiments, analyzed data, finalized figures, and wrote the manuscript.

Acknowledgments
This research was supported by the Barrow Neuroscience Foundation, the BNI-BMS Seed Fund, and CNSF (81771437). These funders have no role in study design, data collection, data analysis, interpretation, writing of the report.

References
[1] Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232(1):54–61.
[2] Schatz AR, Lee M, Condie RB, Pulestki JT, Kaminrski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997;142(2):278–87.
[3] McCoy KL, Matveyea M, Carlisle SJ, Cabral GA. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 1999;289(3):1620–5.
[4] Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004;24(11):7208–15.
[5] Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365(6441):61–5.
[6] Buckley NE, McCoy KL, Mezei E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 2000;396(2–3):141–9.
[7] Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008;153(2):309–18.
[8] Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008;1139:434–49.
[9] Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006;1074:514–36.
[10] Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facchi L, et al. The ALAamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 1996;93(9):3984–9.
[11] Stempel AV, Stumpf A, Zhang HY, Ozdogan T, Pannasch U, Theis AK, et al. Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the Hippocampus. Nature 2016;500(4):795–800.
[12] Lancejo JL, Barroso-Chinea P, Rico AJ, Conte-Perales L, Callen L, Roda E, et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of M. fascicularis. J Psychopharmacol 2011;25(1):97–104.
[13] Liu QR, Pan CH, Hishimoto A, Li CY, Xi ZX, Llorente-Berrizal A, et al. Species differences in cannabinoid receptor 2 (CRN2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 2009;8(5):519–30.
[14] Garcia-Gutierrez MS, Garcia-Bueno R, Zoppi S, Leza JC, Manzanero J. Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated to alterations in Aβ(42)Aβ(40) receptors. Br J Pharmacol 2012 Feb;165(1):951–64.
[15] Navarrete F, Perez-Ortiz JM, Manzanares J. Cannabinoid CB2 receptor-mediated regulation of impulsive-like behaviour in D2/2 mice. Br J Pharmacol 2012;165(1):260–73.
[16] Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310(5746):329–32.
[17] Visconi MT, Oddi S, Latini L, Pasquaerello N, Florenzano F, Bernardi G, et al. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009;29(14):4564–70.
[18] Ashton JC, Friberg D, Darlington CL, Smith PF. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 2006;396(2):113–6.
[19] Efall JL, Zheng Y, Darlington CL, Smith PF. Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 2008;128(9):961–7.
[20] Brusco A, Tagliaferro P, Saez T, Onaivi ES. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. Synapse (New York NY) 2008;62(12):944–5.
[21] Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006;1071(1):10–23.
Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in chick ciliary body. J Neurophysiol 2002;189(6):277–286.

Schmitt W, Schafer F, Strigovi K, Strigovi F. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior in rats following transient focal cerebral ischemia. Neuroscience 2012;237:133–136.

Xi ZQ, Xie X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB receptors modulate dopamine’s actions in mice. Nat Neurosci 2011;14:9:1160–6.

Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 2014;111(46):E5007–12.

Q-S Liu, Pu L, M-P Mm. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 2005;437(7061):1027–31.

Ungless MA, Whitter J, Malenka RC, Bocsi A. Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 2001;411(6837):583–7.

Gao M, Jin Y, Yang K, Zhang D, Luaks RJ, Wu J. Mechanisms involved in systemic nicotine-induced glutamatergic synaptic plasticity on dopamine neurons in the ventral tegmental area. J Neurosci 2010;30(41):13841–52.

Yang K, Buhlmian L, Khan GM, Nichols RA, Jin G, McIntosh JM, et al. Functional nicotinic acetylcholine receptors containing alpha subunits are on GABAergic neural boutons adherent to ventral tegmental area dopamine neurons. J Neurosci 2011;31(7):2537–48.

Wu J, George AA, Schroeder KM, Li X, Westling R, et al. Electrophysiological, pharmacological, and molecular evidence for alpha-7 nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J Pharmacol Exp Ther 2004;311(1):80–91.

Yang K, Hu J, Luercio L, Liu Q, Zeng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Neurophysiol 2006;95(4):2594–611.

Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;82(2):353–43.

Pritchard BL, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 1989;87(7):1219–80.

Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001;356(1407):381–408.

Stott JB, Postovit OY, Carr G, Barrese V, Greenwood IA. G-protein beta-gamma subunits are positive regulators of Kv7.4 and native vascular Kv7 channel activity. Proc Natl Acad Sci U S A 2011;108(21):8697–502.

Schweitzer P. Cannabinoids decrease the K(+) current in hippocampal CA1 neurons. J Neurosci 2000;20(1):51–8.

Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature 1988;338(6211):673–6.

Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors in the brain. J Pharmacol Exp Ther 1987;243(2):278–80.

Yang K, Hu J, Luercio L, Liu Q, Zeng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Neurophysiol 2006;95(4):2594–611.

Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;82(2):353–43.

Pritchard BL, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 1989;87(7):1219–80.

Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001;356(1407):381–408.

Stott JB, Postovit OY, Carr G, Barrese V, Greenwood IA. G-protein beta-gamma subunits are positive regulators of Kv7.4 and native vascular Kv7 channel activity. Proc Natl Acad Sci U S A 2011;108(21):8697–502.

Schweitzer P. Cannabinoids decrease the K(+) current in hippocampal CA1 neurons. J Neurosci 2000;20(1):51–8.

Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature 1988;338(6211):673–6.

Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors in the brain. J Pharmacol Exp Ther 1987;243(2):278–80.

Yang K, Hu J, Luercio L, Liu Q, Zeng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Neurophysiol 2006;95(4):2594–611.

Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;82(2):353–43.

Pritchard BL, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 1989;87(7):1219–80.

Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001;356(1407):381–408.

Stott JB, Postovit OY, Carr G, Barrese V, Greenwood IA. G-protein beta-gamma subunits are positive regulators of Kv7.4 and native vascular Kv7 channel activity. Proc Natl Acad Sci U S A 2011;108(21):8697–502.

Schweitzer P. Cannabinoids decrease the K(+) current in hippocampal CA1 neurons. J Neurosci 2000;20(1):51–8.

Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature 1988;338(6211):673–6.

Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors in the brain. J Pharmacol Exp Ther 1987;243(2):278–80.

Yang K, Hu J, Luercio L, Liu Q, Zeng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Neurophysiol 2006;95(4):2594–611.

Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;82(2):353–43.

Pritchard BL, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 1989;87(7):1219–80.

Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001;356(1407):381–408.

Stott JB, Postovit OY, Carr G, Barrese V, Greenwood IA. G-protein beta-gamma subunits are positive regulators of Kv7.4 and native vascular Kv7 channel activity. Proc Natl Acad Sci U S A 2011;108(21):8697–502.

Schweitzer P. Cannabinoids decrease the K(+) current in hippocampal CA1 neurons. J Neurosci 2000;20(1):51–8.

Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neuron. Nature 1988;338(6211):673–6.

Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors in the brain. J Pharmacol Exp Ther 1987;243(2):278–80.

Yang K, Hu J, Luercio L, Liu Q, Zeng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Neurophysiol 2006;95(4):2594–611.

Koyama S, Appel SB. Characterization of M-current in ventral tegmental area dopamine neurons. J Neurophysiol 2006;82(2):353–43.
[86] Ortega-Alvaro A, Ternianov A, Aracil-Fernandez A, Navarrete F, Garcia-Gutierrez MS, Manzanares J. Role of cannabinoid CB receptor in the reinforcing actions of ethanol. Addict Biol 2015 Jan;20(1):43–55.

[87] Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 2011;63(3):461–70.

[88] Onaivi ES, Ishiguro H, Gu S, Liu QR. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol 2012;26(1):92–103.

[89] Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011;50(2):193–211.